非布索坦属片剂,是抗痛风药。非布索坦对氧化型和还原型的XOR均有显著的抑制作用,因而其降低尿酸的作用更强大、持久,因此本品可用于治疗痛风的慢性高尿酸血症。 该药能有效降低高尿酸血症患者血中尿酸的含量至低于6.0mg/dL的推荐含量,而且罹患轻度至中度肾功能损伤的患者在未调整剂量的情况下,耐受性良好。据估计,日本罹患高尿酸血症的人数在1600万左右。 帝人制药早在1991年发现非布索坦,该药是第一个非嘌呤类黄嘌呤氧化酶选择性抑制剂,其化学结构不同于别嘌呤醇,别嘌呤醇作为高尿酸血症的标准治疗已使用超过40年。 非布索坦以商品名Uloric在美国和加拿大获得批准上市,以商品名Adenuric在欧洲上市 Febuxostat is a selective inhibitor of xanthine oxidase, the enzyme that catalyses the metabolism of purines to uric acid.1 Accumulation of uric acid in the blood, leading to the precipitation of urate crystals in joints and tendons, is responsible for the symptoms of gout. CLINICAL STUDIES Febuxostat was studied in 2 randomised, double-blind, pivotal trials involving 1834 patients with hyperuricaemia (serum uric acid level ≥480 micromoles per litre) and gout. Both studies showed the drug to be more effective than a fixed dose of 300mg allopurinol once daily at lowering blood uric acid levels.2 The first study (APEX), which enrolled 1072 patients, compared 3 once daily doses of febuxostat (80mg, 120mg and a safety dose of 240mg) with placebo and allopurinol over a 6-month period.3 The second study (FACT) compared 2 doses of febuxostat (80mg and 120mg once daily) with allopurinol over 1 year in 762 patients.4 Allopurinol was administered at a dose of 300mg once daily in both studies, except in patients with mild or moderately impaired renal function, who received 100mg daily in the APEX study and were excluded from the FACT study. Febuxostat has not been studied in patients with severe renal impairment. All participants also received either colchicine or naproxen for the first 8 weeks, to prevent gout flares. The primary efficacy endpoint was the number of patients whose final three monthly blood uric acid measurements were below 357 micromoles per litre. In the APEX study, 48 per cent of patients taking febuxostat 80mg and 65 per cent of patients taking febuxostat 120mg had uric acid levels below 357 micromoles per litre on the final three occasions. This was compared with 22 per cent of the patients taking allopurinol and none of the patients taking placebo (p<0.05 for all comparisons). After the 8 eight weeks of treatment, the proportions of patients who required treatment for gout flares were similar in all the groups. Median tophus area decreased by a comparable amount in each group.3 Similar results were seen in the FACT study. After 1 year, the proportion of patients who achieved the target uric acid level was 53 per cent in the febuxostat 80mg group and 62 per cent in the febuxostat 120mg group, compared with 21 per cent of the patients in the allopurinol group (p<0.001 for both comparisons). There were no significant differences between any of the groups in the rate of gout flare or the median reduction in tophus area.4 The most common adverse effects associated with febuxostat are liver function abnormalities, diarrhoea, headache, nausea and rash. There may also be an increased risk of cardiovascular effects; therefore, febuxostat is not recommended in patients with ischaemic heart disease or congestive heart failure.1 The recommended dose of febuxostat is 80mg once daily, increasing to 120mg once daily if uric acid levels remain elevated after 2–4 weeks. As with allopurinol, gout flares can still occur during initial treatment as a result of urate mobilisation from tissue deposits. Consequently, concomitant use of colchicine or an NSAID is recommended for at least the first six months of treatment. Febuxostat should not be initiated during an acute attack of gout.1 Febuxostat is approved by NICE as an option for the management of chronic hyperuricaemia in gout if allopurinol is not tolerated or contraindicated.5 英文药名: Uloric(Febuxostat Tablets) 中文药名: 非布索坦片 【原产地英文商品名】ULORIC 40mg/tablet x 30tablets 美国FDA批准了近40年来的第一个用于治疗高尿酸症的痛风药物——武田制药的非布索坦(febuxostat;ULORIC)。非布索坦通过降低患者血液中的尿酸水平改善来痛风患者的症状。此外,武田制药北美公司还是该产品在美国市场中的独立开发商与销售商。 通用名:非布索坦 适应症:用于治疗痛风的慢性高尿酸血证。 【原产地英文商品名】:ADENURIC 80mg/tablet x 30tablets 药理作用特点 痛风的发生是由于体内产生尿酸过多及肾脏清除能力下降,尿酸体内蓄积,导致尿酸盐结晶在关节及各脏器沉积。因此,痛风的治疗通常采取的手段是:促进尿酸排泄和抑制尿酸生成,并采用适当措施改善相关症状。 体内尿酸的生成与嘌呤代谢有关,在嘌呤代谢的最后步骤中,次黄嘌呤在黄嘌呤氧化还原酶(XOR)的作用下生成黄嘌呤,再进一步生成尿酸,抑制该酶的活性可以有效的减少尿酸的生成。非布索坦为目前世界上最新研制的XOR抑制剂,其通过高度选择性地作用于该氧化酶,减少体内尿酸合成,降低尿酸浓度,从而有效治疗通风疾病。 与别嘌呤相比,非布索坦具有明显优势: 临床评价 一项多中心、双盲、随机Ⅱ期临床研究评价了非布索坦的安全性和对痛风的疗效。总共有136名男性和17名女性痛风病人随机接受安慰剂或本品(40、80或120mg/d),4周后检测发现,本品各剂量组病人血清尿酸浓度较治疗前均显著降低,按剂量由低至高各组分别平均降低37%、44%和59%,而安慰剂组病人仅降低了2%;绝大多数病人坚持完成了试验,本品和安慰剂组不良反应发生率相近,并且这些不良反应大多轻微,具有自限性,常见的有腹泻、疼痛、背痛、头痛和关节痛。 关于非布司他的的临床问题 Important Safety and Other Information ULORIC is a prescription medicine used to lower blood uric acid levels in adults with gout. Individual results may vary. Do not take ULORIC if you are taking Azathioprine (Imuran®, Azasan®), Mercaptopurine (Purinethol®), or Theophylline (Theo-24®, Elixophyllin®, Theochron®, Theolair®, Uniphyl®). For some people, gout may flare up when starting certain gout medicines, including ULORIC. If you have a flare while taking ULORIC, do not stop taking your medicine. Your healthcare provider may give you other medicines to help prevent your gout flares. Heart Problems. A small number of heart attacks, strokes and heart-related deaths were seen in clinical studies. It is not certain that ULORIC caused these events. Your healthcare professional may do blood tests to check your liver function while you are taking ULORIC. The most common side effects are liver problems, nausea, gout flares, joint pain, and rash. Uloric - What You Need to Know Uloric Recommended for FDA Approval Febuxostat: More Effective Than Standard Drug Mismanagement of Gouty Arthritis Not Uncommon Gout - 10 Things You Should Know Fast Facts About Gout Gout Screening Quiz Gout Risk Factor Quiz How to Recognize the Signs and Symptoms of Gout The Gout Quiz - Test Your Knowledge of Gout How To Treat Gout With Diet And Medication The Gout Guide: Free E-Course Newsletter New Gout Drug Gets FDA Panel Nod Currently, allopurinol (trade name, Zyloprim) is the only FDA-approved drug that prevents formation of the uric acid crystals that cause gout. However, side effects -- including potentially fatal reactions -- limit the amount of allopurinol that can be tolerated. Most gout patients do not receive fully effective doses of allopurinol. In clinical trials sponsored by Takeda, Uloric's manufacturer, an 80-milligram dose of Uloric worked better than allopurinol; a 40-milligram dose worked at least as well as allopurinol. Unlike allopurinol, very little Uloric is excreted through the urine, making Uloric safe for patients with kidney problems. Gout patients with impaired kidney function have to take very low doses of allopurinol, making the drug even less effective for these patients. In 2005, the FDA refused to approve Uloric because there were slightly more deaths and heart problems in patients taking the drug than in patients taking allopurinol. As people with gout problems already are at higher risk of heart disease, the FDA issued an "approvable" letter, noting that Uloric could be approved if this safety question were addressed. Takeda then performed a large new phase 3 clinical trial that enrolled more gout patients than the two previous phase 3 trials combined. The new study found no more deaths and no more heart problems in patients taking Uloric than in patients taking allopurinol. Based on the safety and efficacy data, the FDA panel recommended by a 12-0 vote that the FDA approve Uloric at both the 40-milligram and 80-milligram doses. Takeda suggests the higher dose is more effective in subjects with more severe gout. Takeda has offered to continue studying Uloric after FDA approval. A phase 4 clinical trial would compare Uloric to allopurinol for the reduction of gout flare-ups. And because drugs with the same mechanism of action as Uloric and allopurinol may affect theophylline bronchodilators, Takeda has agreed to conduct a postmarketing phase 1 study of Uloric's interactions with theophylline. Gout occurs when blood levels of uric acid rise. At blood levels above 7 mg/dL -- and above 6 mg/dL in the extremities -- crystals can form that lodge in the joints and other body tissues. These crystal deposits provoke an immune response that results in extremely painful swelling and in inflammatory arthritis that can permanently destroy the joints. (For more on the causes, symptoms, and treatment of gout, see WebMD's Gout Pictures Slideshow.) About 1.4% of men and 0.6% of women have gout. But prevalence rises with age. After age 80, about 9% of men and 6% of women develop gout. The body converts a chemical called xanthine into uric acid via an enzyme called xanthine oxidase or XO. Allopurinol and Uloric each inhibit XO and prevent the formation of uric acid. Allopurinol is approved in doses up to 800 milligrams. However, it's rarely dosed above 300 milligrams per day and is often ineffective. Allopurinol side effects include upset stomach, headache, diarrhea, and rash. Although rare, allopurinol hypersensitivity syndrome can develop. It's fatal 20% to 30% of the time. The most common side effects seen in patients taking Uloric during clinical trials were upper respiratory tract infections, muscle and connective-tissue symptoms, and diarrhea. The drug was well tolerated, and these side effects did not increase over long-term use. |
非布索坦片Adenuric(febuxostat Tablets)简介:非布索坦属片剂,是抗痛风药。非布索坦对氧化型和还原型的XOR均有显著的抑制作用,因而其降低尿酸的作用更强大、持久,因此本品可用于治疗痛风的慢性高尿酸血症。日本帝人制药株式会社于5月17日在日本推 ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多 |